ABI
PODD icon

Adamant Biomedical Investments’s Insulet PODD Stock Holding History

Adamant Biomedical Investments’s Portfolio PODD Stock Details PODD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-80,000
Closed -$2.95M – 102
2014
Q3 		$2.95M Buy
+80,000
New +$2.92M 0.74% 47

Other funds holding PODD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Adamant Biomedical Investments's PODD Position: Q4 2014 in Review

Adamant Biomedical Investments sold out of Insulet (PODD) in Q4 2014, closing a stake of 80,000 shares — an estimated $2.95M sold.

Adamant Biomedical Investments first reported a position in PODD in Q3 2014 and held it in 1 quarter. The position peaked at $2.95M in Q3 2014. 176 funds tracked by Wall St. Rank hold PODD as of Q4 2014.

  • Adamant Biomedical Investments reported no remaining Insulet position as of Q4 2014 after selling out during the quarter.
  • Adamant Biomedical Investments sold 80,000 Insulet shares in Q4 2014, an estimated $2.95M.
  • Adamant Biomedical Investments first reported a position in Insulet in Q3 2014 and held it in 1 quarter.
  • Adamant Biomedical Investments's Insulet position peaked at $2.95M in Q3 2014.
  • 176 funds tracked by Wall St. Rank held Insulet as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.